- Study protocol
- Open Access
- Open Peer Review
Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial
BMC Pediatrics volume 11, Article number: 102 (2011)
Randomized controlled trials have shown that treatment of chronically ventilated preterm infants after the first week of life with dexamethasone reduces the incidence of the combined outcome death or bronchopulmonary dysplasia (BPD). However, there are concerns that dexamethasone may increase the risk of adverse neurodevelopmental outcome. Hydrocortisone has been suggested as an alternative therapy. So far no randomized controlled trial has investigated its efficacy when administered after the first week of life to ventilated preterm infants.
The SToP-BPD trial is a randomized double blind placebo controlled multicenter study including 400 very low birth weight infants (gestational age < 30 weeks and/or birth weight < 1250 grams), who are ventilator dependent at a postnatal age of 7 - 14 days. Hydrocortisone (cumulative dose 72.5 mg/kg) or placebo is administered during a 22 day tapering schedule. Primary outcome measure is the combined outcome mortality or BPD at 36 weeks postmenstrual age. Secondary outcomes are short term effects on the pulmonary condition, adverse effects during hospitalization, and long-term neurodevelopmental sequelae assessed at 2 years corrected gestational age. Analysis will be on an intention to treat basis.
This trial will determine the efficacy and safety of postnatal hydrocortisone administration at a moderately early postnatal onset compared to placebo for the reduction of the combined outcome mortality and BPD at 36 weeks postmenstrual age in ventilator dependent preterm infants.
Trial registration number
Netherlands Trial Register (NTR): NTR2768
Bronchopulmonary dysplasia (BPD) is the most common complication of premature birth, with a reported incidence of 8% to 35% [1, 2]. BPD is characterized by chronic respiratory distress, the need for prolonged respiratory support, an increased risk of recurrent pulmonary infections leading to hospital readmissions during the first years of life , and life-long alterations in lung function [4–6]. BPD is also considered an important risk factor for adverse neurodevelopmental outcome after premature birth [7–11]. These long-term consequences of BPD place a heavy burden on societal and health care costs [12–15].
Pulmonary inflammation has been identified as an important risk factor in the development of BPD, providing the rationale for treating patients at risk for BPD with glucocorticoids, a group of drugs well known for its strong anti-inflammatory effect [16–18]. Randomized controlled trials (RCTs) comparing dexamethasone to placebo in ventilated preterm infants at risk for BPD have shown that dexamethasone reduces the incidence of the combined outcome death or BPD [19, 20]. Dexamethasone seems to be most effective when initiated between 7 to 14 days postnatal age, the so-called moderately early treatment onset [21, 22]. Unfortunately, more recent follow-up studies seem to indicate that this beneficial effect on the lung may be outweighed by an increased risk of adverse neurodevelopmental outcome. Despite the fact that this adverse effect on the newborn brain has so far only been reported in studies investigating the early use of dexamethasone (i.e. initiated < 7 days of postnatal age), there is now a general concern on its use in preterm infants [23–25]. Based on this concern, the American Academy of Pediatrics, Canadian Paediatric Society, and the European Association of Perinatal Medicine have stated that the use of dexamethasone should be restricted to exceptional cases and clinical trials should be performed to investigate the use of alternative anti-inflammatory glucocorticoids, such as hydrocortisone [26, 27].
In response to this statement the use of dexamethasone has dropped dramatically to approximately 10% of the preterm infants at risk for BPD [28–30]. In addition, its dose has been significantly reduced and administration is often postponed until the 3rd or 4th week of life .
Some clinicians have started to use hydrocortisone, as an alternative for dexamethasone. Animal studies have suggested that, in contrast to dexamethasone, hydrocortisone has no detrimental effect on the brain . To date, eight RCTs including 880 preterm infants investigated a low hydrocortisone dose started within 72 hours after birth (early treatment onset). Meta-analysis of these trials failed to show a clear reduction in the incidence of death or BPD . Only one of these trials reported long-term follow-up, showing no differences in adverse neurodevelopmental sequelae .
To our knowledge, there are no placebo controlled randomized trials that investigated the use of hydrocortisone after the first week in life in ventilator dependent preterm infants  The neonatal intensive care unit (NICU) at the University Medical Center Utrecht has historically used hydrocortisone after the first week of life for ventilated preterm infants at high risk for developing BPD. Retrospective cohort studies conducted in this center seem to indicate that hydrocortisone is effective in reducing BPD, without causing serious long-term adverse effects [35–37]. However, these findings need to be confirmed or refuted by a large randomized placebo controlled trial.
Aim of the study
To investigate if systemic hydrocortisone, started between 7 - 14 days after birth, is safe and effective in reducing the incidence of the combined outcome death or BPD at 36 weeks PMA in chronically ventilated preterm infants, as compared to a placebo.
Multicenter randomized double-blind placebo-controlled trial conducted in 15 NICUs in the Netherlands (n = 10) and Belgium (n = 5). The inclusion period will be 3 years, with a 2 year follow-up for each child.
Preterm infants with:
- gestational age < 30 wks and/or birth weight < 1250 g
- ventilator dependency at 7-14 days PNA
- respiratory index (RI), defined as the product of mean airway pressure (MAwP) and the fraction of inspired oxygen (FiO2), of ≥ 3.5 for more than 12 h/day for at least 48 hours, ensuring adequate oxygen saturation (85-95%) and PaCO2 values (5.0-7.5 kPa).
- chromosomal defects (e.g. trisomy 13, 18, 21)
- major congenital malformations that:
○ compromise lung function (e.g. surfactant protein deficiencies, congenital diaphragmatic hernia)
○ result in chronic ventilation (e.g. Pierre Robin sequence)
○ increase the risk of death or adverse neurodevelopmental outcome (e.g. congenital cerebral malformations)
use of dexamethasone or hydrocortisone prior to inclusion for the sole purpose of improving lung function and respiratory status
Sample size calculation
Estimating the a priori risk of death or BPD in preterm infants less than 30 weeks gestation and ventilated in the second week of life at 60 - 70% and defining an absolute risk reduction of 15% or more (NNT = 7) as clinically relevant, 175 patients need to be included in each treatment arm (type I error of 5%, power of 80%). Anticipating a 10% drop out of randomized patients, the number of inclusions needs to be increased to 200 patients in each arm (total 400 patients).
Treatment of subjects
Trial medication and dosing
Trial medication will be prepared and distributed according to Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) guidelines. Using a double-blinded treatment design, infants will be allocated to either hydrocortisone or placebo treatment.
The optimal (cumulative) dose of hydrocortisone is currently unknown. Pharmacokinetic studies have not been done, and are tedious in this field of developmental endocrinology. However, the NICU of the University Medical Center in Utrecht (the Netherlands) has used a fixed hydrocortisone treatment regimen for several decades, which has recently been adopted by 4 other Dutch NICUs. Retrospective cohort studies have suggested that this treatment regimen is equally effective in reducing death or BPD compared with dexamethasone treated infants without causing an increased risk of adverse neurological outcome [36, 38]. Based on these findings and current clinical practice in the Netherlands, we decided to adopt the dosing regimen from Utrecht for this study. Infants in the hydrocortisone group will be treated with hydrocortisone 5 mg/kg/day Q.I.D for 7 days, followed by 3.75 mg/kg/day T.I.D. for 5 days, subsequently lowering the frequency by one dose every 5 day. This leads to a total duration of therapy of 22 days and a cumulative dose of 72.5 mg/kg hydrocortisone. The infants in the control group receive a placebo treatment for the entire 22-day period in the same frequency as the hydrocortisone group. Both hydrocortisone and placebo schedules will be calculated according to weight on the day of randomization and not adjusted to the actual weight during the tapering schedule.
Treatment failure and use of open label hydrocortisone
In general, the use of open label hydrocortisone during the 22 day treatment course is strongly discouraged. Open label hydrocortisone use may be considered in the following conditions:
1. The pulmonary condition is progressively deteriorating and the RI > 10 for more than 6 consecutive hours
2. The pulmonary condition of the patient is stable (RI ≤ 10) but not improving over time. If this is the case, open label hydrocortisone may be considered if both of the following conditions are met:
Extubation was attempted (extubation trial) within 24 hours before considering open label treatment and this attempt failed
The patient has been on study medication for at least 10 days
If, based on the aforementioned criteria, the physician decides to start open label hydrocortisone, the study medication is stopped and the patient will be recorded as "treatment failure". The open label hydrocortisone dosage schedule is similar to that used in the study. In case of treatment failure the following data will be collected: timing of treatment failure, ventilator support and settings, type of open label medication, starting date, cumulative dose and duration of open label therapy. These patients will be followed as all other patients.
Late rescue hydrocortisone therapy
If a patient is still on mechanical ventilation after completion of the study medication (i.e. day 22) and a subsequent extubation attempt failed, the physician may consider treatment with late rescue hydrocortisone. The late rescue hydrocortisone dosing schedule is similar to that used in the study. Data on the starting date, cumulative dose and duration of rescue therapy are collected. The patients will be followed as all other patients.
Hydrocortisone for hypotension
In case of persistent hypotension, not (sufficiently) responding to first line treatment with intravascular volume expansion and inotropes (i.e. dopamine and/or dobutamine) the use of hydrocortisone is allowed in a dose of 3 mg/kg/day for 5 days . The use of hydrocortisone for this indication will not be considered as treatment failure. Data on timing, dose and duration will be collected.
The use of inhaled corticosteroids in the first weeks of life is strongly discouraged. However, its use is not an exclusion criterion, because there is currently insufficient evidence that inhaled corticosteroids will reduce the risk of death or BPD in preterm infants. Data on timing, dose and duration will be collected.
Use of co-intervention
All randomized patients will be subjected to co-interventions, such as respiratory support and co-medication, according to the guidelines and protocols of the individual NICUs.
Eligible patients can be randomized between day 7 and 14 PNA. The first dose of study medication should be administered within 24 hours after randomization. Randomization will be centrally controlled and web-based using a computer program designed for this study. This trial will be protected from selection bias by using concealed, stratified and blocked randomization. Randomization will be stratified per center and according to gestational age stratum (stratum A: < 27 weeks; stratum B: ≥ 27 weeks) and the allocation ratio will be 1:1 using variable block sizes. Multiple birth infants will be randomized independently, unless the parents or caregivers explicitly request that the siblings are allocated to the same treatment arm. In case of the latter the randomization software will be able to perform twin randomization. The infants' parents and all members of the medical team, including investigators, remain blinded to group assignment throughout the study.
Withdrawal of individual subjects
Parents or caregivers may decide to withdraw their infant from the study at any time and without any consequences. Subjects withdrawn from the study will be treated according to the standard of care, including neurodevelopmental outcome assessment at the outpatient clinic. To ensure adequate inclusion, withdrawn patients will be replaced by additional inclusions.
The primary outcome will be the dichotomous combined outcome death or BPD at 36 weeks PMA. BPD at 36 weeks PMA will be assessed according to the NICHD Consensus Statement using the classification of severity as proposed by Jobe et.al.  and if indicated the oxygen reduction test as described by Walsh et.al. [18, 40, 41].
Secondary outcomes before hospital discharge
mortality at 28 days PNA, 36 weeks PMA and at hospital discharge
BPD at 28 days
failure to extubate 3, 7, 14 and 21 days after initiating therapy
duration of mechanical ventilation
use of late rescue hydrocortisone treatment
total time on supplemental oxygen
length of hospital stay
hypertension, as previously defined
hyperglycemia requiring the use of insulin therapy
nosocomial infection, including clinical or culture proven sepsis, meningitis and pneumonia
patent ductus arteriosus for which medical intervention or surgical ligation is needed
necrotising enterocolitis (NEC) with Bell stage II or more
spontaneous intestinal perforation
intraventricular haemorrhage (IVH) and/or periventricular leucomalacia (PVL), including grading on cerebral ultrasonography according to protocol as defined by Ment et.al. 
retinopathy of prematurity, including grading according to international classification 
weight, head circumference and length at 36 weeks PMA
Secondary outcomes after hospital discharge
number of readmissions since first discharge home
weight, length and head circumference at 24 months corrected age (c.a.)
Bayley Scales of Infant Development III, Mental Developmental Index and Psychomotor Developmental Index at 24 months c.a.
cerebral palsy and severity of cerebral palsy using gross motor function classification system at 24 months c.a.
hearing loss requiring hearing aids at 24 months c.a.
blindness at 24 months c.a.
behavioral problems (child behavior checklist) at 24 months c.a.
Data collection and statistical analysis
At the time of inclusion and randomization, baseline data will be collected from all patients, including maternal and patient characteristics, respiratory status and support, and the presence of serious morbidity as listed in the secondary outcomes. During the 22 d treatment course, respiratory support, blood gas analyses, serum glucose levels, blood pressure and anthropometric data will be collected on a daily bases. Outcome variables and co-interventions will be recorded at 36 weeks PMA, hospital discharge and at follow-up (2 years corrected age).
Data on eligible patients not included in the study will also be recorded, including patient characteristics, respiratory status and support, and the reason why the patient was not included in the trial.
Data will be presented as mean ± standard deviations or medians and (interquartile) ranges depending on their distribution. Categorical data will be analyzed using the Chi-square test. Continuous data will be analyzed using the Student's t test or Mann-Whitney test as appropriate. Both intention-to-treat and per-protocol analysis will be employed since use of open label glucocorticoids may modulate possible treatment effects . The effect of hydrocortisone on the primary outcome BPD free survival will be assessed by multi-variable logistic regression analysis including possible confounders. Statistical significance is set at p < 0.05.
Safety aspects and study monitoring
During the study all patients will be closely monitored for adverse events. First, complications of preterm birth and intensive care treatment, as listed in the outcome section of this study protocol, will be reported once a year to the Data Monitoring Committee (DMC) and the Ethics Committee that approved the study protocol. Second, all adverse events, not listed as outcomes in this study will be reported within the appropriate time frame to the Data Monitoring Committee (DMC) and the Ethics Committee that approved the study protocol. Finally, to enhance safety of this study the principle investigator and the study coordinator will be automatically informed by email in case a patient
is treated with indomethacin or ibuprofen while receiving study medication;
is diagnosed as having an intestinal perforation;
is diagnosed as having hypertension; and
receives open label hydrocortisone.
In addition to the above, the DMC will monitor efficacy and safety outcomes and will provide the trial's Steering Committee with recommendations regarding continuing or stopping the trial (for all patients or subgroups of patients) when approximately 25% (safety only), 50% (safety and efficacy) and 75% (safety and efficacy) of the anticipated outcome data are available. The DMC will be blinded to the treatment allocation, but may request the data manager to reveal the allocation labels.
The study will be monitored by means of personal visits to the investigators' facilities and through other communications (e.g., telephone calls, written correspondence). The main goal of monitoring is to evaluate the progress of the study, ensure the rights and wellbeing of the subjects are protected, check that the reported clinical study data are accurate, complete and verifiable from source documents, and the conduct of the study is in compliance with the approved protocol and amendments, GCP and applicable national regulatory requirements. A monitoring visit will include a review of the essential clinical study documents (regulatory documents, CRFs, source documents, drug disposition records, subject informed consent forms, etc.) as well as discussion on the conduct of the study with the investigator and staff.
In case of hypertension defined as a systolic blood pressure > 80 mmHg for infants with a gestational age of 24-26 wks, > 90 mmHg for infants 26-28 wks, and > 100 mmHg for infants ≥ 28 wks, the hydrocortisone dose is lowered according to a predefined tampering schedule. Data on the time, reason and dose adjustment will be collected.
The study will be conducted according to the principles of the Declaration of Helsinki  and in accordance with the Medical Research Involving Human Subjects Act (WMO). Patients can only be included in the study after obtaining written informed consent from both parents. Both parents will receive verbal and written information on all aspects of the study, including possible risks and benefits. The right of a parent to refuse participation without a given reason will be respected. The parents will remain free to withdraw their child at any time from the study without consequences for further treatment. The study protocol has been reviewed and approved by the Ethics Committee of the Academic Medical Center in Amsterdam (the Netherlands) and the local Ethics Committee of each participating hospital.
Handling and storage of data and documents
Data management will be implemented according to GCP guidelines. Patient data will be entered via an electronic case record form (CRF) in a central GCP proof web-based database to facilitate on-site data-entry. Security is guaranteed with login names, login codes and encrypted data transfer. The data of all subjects will be coded and this coding will not be retraceable to the individual patient. The key to this coding is safeguarded by the investigator. Access will be granted to the principal investigator, local investigator, the study monitor, quality assurance auditor, the Ethics Committee and the inspector of the Ministry of Health. Data will be stored for 15 years.
Case Record Form
Data Monitoring Committee
Good Clinical Practice
Good Manufacturing Practice
Mean Airway Pressure
Neonatal Intensive Care Unit
National Institutes for Child Health and Human Development
Number Needed to Treat
Randomised Controlled Trial
Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, Verter J, Temprosa M, Wright LL, Ehrenkranz RA, et al: Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics. 2001, 107: E1-10.1542/peds.107.1.e1.
Hentschel J, Berger TM, Tschopp A, Muller M, Adams M, Bucher HU: Population-based study of bronchopulmonary dysplasia in very low birth weight infants in Switzerland. Eur J Pediatr. 2005, 164: 292-297. 10.1007/s00431-005-1623-1.
Kinsella JP, Greenough A, Abman SH: Bronchopulmonary dysplasia. Lancet. 2006, 367: 1421-1431. 10.1016/S0140-6736(06)68615-7.
Doyle LW: Respiratory function at age 8-9 years in extremely low birthweight/very preterm children born in Victoria in 1991-1992. Pediatr Pulmonol. 2006, 41: 570-576. 10.1002/ppul.20412.
Doyle LW, Faber B, Callanan C, Freezer N, Ford GW, Davis NM: Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics. 2006, 118: 108-113. 10.1542/peds.2005-2522.
Jacob SV, Coates AL, Lands LC, MacNeish CF, Riley SP, Hornby L, Outerbridge EW, Davis GM, Williams RL: Long-term pulmonary sequelae of severe bronchopulmonary dysplasia. J Pediatr. 1998, 133: 193-200. 10.1016/S0022-3476(98)70220-3.
Walsh MC, Morris BH, Wrage LA, Vohr BR, Poole WK, Tyson JE, Wright LL, Ehrenkranz RA, Stoll BJ, Fanaroff AA: Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatr. 2005, 146: 798-804. 10.1016/j.jpeds.2005.01.047.
Dammann O, Leviton A, Bartels DB, Dammann CE: Lung and brain damage in preterm newborns. Are they related? How? Why?. Biol Neonate. 2004, 85: 305-313. 10.1159/000078175.
Short EJ, Kirchner HL, Asaad GR, Fulton SE, Lewis BA, Klein N, Eisengart S, Baley J, Kercsmar C, Min MO, et al: Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system. Arch Pediatr Adolesc Med. 2007, 161: 1082-1087. 10.1001/archpedi.161.11.1082.
Short EJ, Klein NK, Lewis BA, Fulton S, Eisengart S, Kercsmar C, Baley J, Singer LT: Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics. 2003, 112: e359-10.1542/peds.112.5.e359.
Lewis BA, Singer LT, Fulton S, Salvator A, Short EJ, Klein N, Baley J: Speech and language outcomes of children with bronchopulmonary dysplasia. J Commun Disord. 2002, 35: 393-406. 10.1016/S0021-9924(02)00085-0.
Wang B, Chen Y, Zhang J, Li J, Guo Y, Hailey D: A preliminary study into the economic burden of cerebral palsy in China. Health Policy. 2008, 87: 223-234. 10.1016/j.healthpol.2008.01.001.
Hoving MA, Evers SM, Ament AJ, van Raak EP, Vles JS: Intractable spastic cerebral palsy in children: a Dutch cost of illness study. Dev Med Child Neurol. 2007, 49: 397-398. 10.1111/j.1469-8749.2007.00397.x.
Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment--United States, 2003. MMWR Morb Mortal Wkly Rep. 2004, 53: 57-59.
Beecham J, O'Neill T, Goodman R: Supporting young adults with hemiplegia: services and costs. Health Soc Care Community. 2001, 9: 51-59. 10.1046/j.1365-2524.2001.00279.x.
Carlton DP, Albertine KH, Cho SC, Lont M, Bland RD: Role of neutrophils in lung vascular injury and edema after premature birth in lambs. J Appl Physiol. 1997, 83: 1307-1317.
Ferreira PJ, Bunch TJ, Albertine KH, Carlton DP: Circulating neutrophil concentration and respiratory distress in premature infants. J Pediatr. 2000, 136: 466-472. 10.1016/S0022-3476(00)90009-X.
Jobe AH, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001, 163: 1723-1729.
Halliday HL, Ehrenkranz RA, Doyle LW: Late > 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009, CD001145-
Halliday HL, Ehrenkranz RA, Doyle LW: Early < 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009, CD001146-
Onland W, De Jaegere APMC, Offringa M, van Kaam AHLC: Effects of a higher versus a lower dexamethasone dose on pulmonary and neurodevelopmental sequelae in preterm infants at risk for chronic lung disease: a meta-analysis. Pediatrics. 2008, 122: 92-101. 10.1542/peds.2007-2258.
Onland W, Offringa M, De Jaegere AP, van Kaam AH: Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics. 2009, 123: 367-377. 10.1542/peds.2008-0016.
Eichenwald EC, Stark AR: Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia?. Arch Dis Child Fetal Neonatal Ed. 2007, 92: F334-F337. 10.1136/adc.2006.106583.
Barrington KJ: The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001, 1: 1-10.1186/1471-2431-1-1.
Jobe AH: Postnatal corticosteroids for preterm infants--do what we say, not what we do. N Engl J Med. 2004, 350: 1349-1351. 10.1056/NEJMe048031.
American Academy of Pediatrics, Committee on Fetus and Newborn and Canadian Paediatric Society, Fetus and Newborn Committee: Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002, 109: 330-338. 10.1542/peds.109.2.330.
Halliday HL: Guidelines on neonatal steroids. Prenat Neonat Med. 2001, 6: 371-373.
Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee SK, Ohlsson A: Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics. 2006, 118: e1328-e1335. 10.1542/peds.2006-0359.
Shinwell ES, Lerner-Geva L, Lusky A, Reichman B: Less postnatal steroids, more bronchopulmonary dysplasia. A population-based study in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed. 92: F30-F33.
Shinwell ES, Karplus M, Bader D, Dollberg S, Gur I, Weintraub Z, Arnon S, Gottfreid E, Zaritsky A, Makhoul IR, et al: Neonatologists are using much less dexamethasone. Arch Dis Child Fetal Neonatal Ed. 2003, 88: F432-F433. 10.1136/fn.88.5.F432.
Huang CC, Lin HR, Liang YC, Hsu KS: Effects of neonatal corticosteroid treatment on hippocampal synaptic function. Pediatr Res. 2007, 62: 267-270. 10.1203/PDR.0b013e318123f744.
Doyle LW, Ehrenkranz RA, Halliday HL: Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology. 2010, 98: 111-117. 10.1159/000279992.
Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ, Abbasi S, Cole CH, Aucott SW, Thilo EH, et al: Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics. 2007, 120: 40-48. 10.1542/peds.2006-3158.
Rademaker KJ, de Vries LS, Uiterwaal CS, Groenendaal F, Grobbee DE, van BF: Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up. Arch Dis Child Fetal Neonatal Ed. 2008, 93: F58-F63. 10.1136/adc.2007.119545.
Lodygensky GA, Rademaker K, Zimine S, Gex-Fabry M, Lieftink AF, Lazeyras F, Groenendaal F, de Vries LS, Huppi PS: Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics. 2005, 116: 1-7. 10.1542/peds.2004-1275.
Rademaker KJ, Uiterwaal CS, Groenendaal F, Venema MM, van BF, Beek FJ, van H, Grobbee DE, de Vries LS: Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr. 2007, 150: 351-357. 10.1016/j.jpeds.2006.10.051.
van der Heide-Jalving M, Kamphuis PJ, van der Laan MJ, Bakker JM, Wiegant VM, Heijnen CJ, Veen S, van BF: Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone?. Acta Paediatr. 2003, 92: 827-835. 10.1111/j.1651-2227.2003.tb02541.x.
Karemaker R, Heijnen CJ, Veen S, Baerts W, Samsom J, Visser GH, Kavelaars A, van Doornen LJ, van BF: Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res. 2006, 60: 745-750. 10.1203/01.pdr.0000246200.76860.de.
Ng PC, Lee CH, Bnur FL, Chan IH, Lee AW, Wong E, Chan HB, Lam CW, Lee BS, Fok TF: A double-blind, randomized, controlled study of a "stress dose" of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics. 2006, 117: 367-375. 10.1542/peds.2005-0869.
Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, Everette R, Peters N, Miller N, Muran G, et al: Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 2004, 114: 1305-1311. 10.1542/peds.2004-0204.
Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A: Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003, 23: 451-456. 10.1038/sj.jp.7210963.
Ment LR, Bada HS, Barnes P, Grant PE, Hirtz D, Papile LA, Pinto-Martin J, Rivkin M, Slovis TL: Practice parameter: neuroimaging of the neonate: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2002, 58: 1726-1738.
The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005, 123: 991-999.
Onland W, van Kaam AH, De Jaegere AP, Offringa M: Open-label glucocorticoids modulate dexamethasone trial results in preterm infants. Pediatrics. 2010, 126: e954-e964. 10.1542/peds.2010-0597.
World Medical Association: Declaration of Helsinki Tokyo. 2004
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2431/11/102/prepub
This trial is funded by a Project Grant from the The Netherlands Organisation for Health Research and Development ZonMW Priority Medicines for Children no. 11-32010-02.
The authors declare that they have no competing interests.
WO, ADJ, MO, AvK were involved in drafting the conception and design of the study. All other authors were involved in the final consensus process of the protocol and contributed significantly to the final version. WO, ADJ, MO, AvK drafted the manuscript and all other authors read, edited and approved the final manuscript.